Press Releases

Press Releases

Schrödinger, Inc. Reports Second Quarter 2020 Financial Results and Business Updates

Total revenue of $23.1 million , up 21% year-over-year Software revenue of $20.9 million , up 44% year-over-year New strategic agreements with Thermo Fisher and Viva Biotech  Rapid progress across internal pipeline; three programs in late-stage discovery Conference call today, Monday, August 10,
August 10, 2020

Schrödinger to Host Second Quarter 2020 Financial Results Conference Call and Webcast

NEW YORK --(BUSINESS WIRE)--Aug. 3, 2020-- Schrödinger (Nasdaq: SDGR), whose physics-based software platform enables discovery of high-quality, novel molecules for therapeutics and materials, today announced that it will host a conference call and webcast on Monday, August 10, 2020 at 8:30 a.m.
August 3, 2020

Schrödinger and Viva Biotech Announce Strategic Collaboration to Generate and Interrogate Structures for Unsolved Targets

Collaboration aims to enable discovery of first-in-class therapeutic candidates NEW YORK & SHANGHAI --(BUSINESS WIRE)--Jul. 28, 2020-- Schrödinger, Inc. (Nasdaq: SDGR) and Viva Biotech Holdings (1873.HK) today announced a strategic collaboration to expand the reach of structure-based drug discovery
July 28, 2020

Schrödinger Announces Strategic Collaboration With Thermo Fisher Scientific to Expand Structure-Based Drug Discovery to Novel Targets Using Cryo-EM

NEW YORK --(BUSINESS WIRE)--Jun. 23, 2020-- Schrödinger (Nasdaq:SDGR) today announced a strategic collaboration with Thermo Fisher Scientific to extend the use of cryo-EM in connection with in silico compound screening to accelerate drug discovery. The collaboration brings together Schrödinger’s
June 23, 2020

Schrödinger Expands Discovery Efforts for COVID-19 Alliance with Advanced Molecular Simulation Leveraging High-Powered Parallel Computing on Google Cloud

NEW YORK --(BUSINESS WIRE)--Jun. 23, 2020-- Schrödinger (Nasdaq: SDGR), whose physics-based software platform enables discovery of high-quality, novel molecules for therapeutics and materials, today announced a significant expansion of its work to discover novel antiviral therapeutics for COVID-19
June 23, 2020

Schrödinger to Present at the BMO 2020 Prescriptions for Success Healthcare Conference

NEW YORK --(BUSINESS WIRE)--Jun. 16, 2020-- Schrödinger (Nasdaq: SDGR), whose physics-based software platform enables discovery of high-quality, novel molecules for therapeutics and materials, today announced that members of the management team will participate in a fireside chat at the BMO 2020
June 16, 2020

Schrödinger to Present at the Jefferies 2020 Virtual Healthcare Conference

NEW YORK --(BUSINESS WIRE)--May 28, 2020-- Schrödinger (Nasdaq: SDGR), whose physics-based software platform enables discovery of high-quality, novel molecules for therapeutics and materials, today announced that members of the management team will participate in a fireside chat at the Jefferies
May 28, 2020

Schrödinger Reports First Quarter 2020 Financial Results and Recent Business Updates

Total revenue of $26.2 million and strong growth of 26% year-over-year Record software revenue of $23.8 million , up 28% year-over-year Raised $209.6 million in net proceeds through initial public offering Conference call today, Wednesday, May 13, 2020 at 8:30 a.m.
May 13, 2020

Schrödinger to Host First Quarter 2020 Financial Results Conference Call and Webcast

NEW YORK --(BUSINESS WIRE)--May 6, 2020-- Schrödinger (Nasdaq: SDGR), whose physics-based software platform enables discovery of high-quality, novel molecules for therapeutics and materials, today announced that it will host a conference call and webcast on Wednesday, May 13, 2020 at 8:30 a.m.
May 6, 2020

Schrödinger Strengthens Board of Directors with Appointments of Jeffrey Chodakewitz, M.D., and Gary Ginsberg

NEW YORK --(BUSINESS WIRE)--May 4, 2020-- Schrödinger (Nasdaq: SDGR), whose physics-based software platform enables discovery of high-quality, novel molecules for therapeutics and materials, today announced the appointments of Jeffrey A. Chodakewitz , M.D., and Gary Ginsberg to its Board of
May 4, 2020
Displaying 11 - 20 of 25
Back To Top